Summit Therapeutics Inc. (NASDAQ: SMMT) announced on November 18, 2026, the initiation of the global Phase III HARMONi-10 clinical trial. The study is designed to evaluate ivonescimab, an investigational bispecific antibody, against durvalumab as consolidation therapy in patients with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC). The trial targets patients who have not experienced disease progression following platinum-based concurrent chemoradiation therapy.
HARMONi-10 is a multi-regional, open-label, potentially registration-enabling Phase III study. The primary endpoint of the trial is progression-free survival (PFS). Global clinical trial site activations for the study are expected to begin in the fourth quarter of 2026.
Summit Therapeutics describes ivonescimab as a potential first-in-class investigational bispecific antibody that combines the effects of immunotherapy via PD-1 blockade with anti-angiogenesis effects associated with blocking VEGF. The company notes that ivonescimab was initially approved for marketing authorization in China in May 2024. The therapy is not yet approved by regulatory authorities in the United States or Europe.
This study marks Summit’s sixth sponsored Phase III study of ivonescimab and its fourth in NSCLC, following the HARMONi, HARMONi-3, and HARMONi-7 trials. The company reports that over 5,000 patients have been treated with ivonescimab in clinical studies globally, and over 100,000 patients when considering those treated in a commercial setting in China.